Skip to Content

Vedolizumab Dosage

Applies to the following strength(s): 300 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Crohn's Disease - Maintenance

Ulcerative colitis and Crohn's disease: 300 mg IV at zero, two and six weeks and then every eight weeks thereafter.

Comments: Discontinue if no evidence of therapeutic benefit by Week 14.

Uses:
Adult Ulcerative Colitis (UC):
Adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for inducing and maintaining clinical response or remission, improving endoscopic appearance of the mucosa, or achieving corticosteroid-free remission.

Adult Crohn's Disease(CD):
Adults with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for achieving clinical response or remission, or achieving corticosteroid-free remission.

Usual Adult Dose for Ulcerative Colitis

Ulcerative colitis and Crohn's disease: 300 mg IV at zero, two and six weeks and then every eight weeks thereafter.

Comments: Discontinue if no evidence of therapeutic benefit by Week 14.

Uses:
Adult Ulcerative Colitis (UC):
Adults with moderately to severely active UC who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for inducing and maintaining clinical response or remission, improving endoscopic appearance of the mucosa, or achieving corticosteroid-free remission.

Adult Crohn's Disease(CD):
Adults with moderately to severely active CD who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. This drug is used for achieving clinical response or remission, or achieving corticosteroid-free remission.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for additional precautions.

Safety and efficacy have not been established in patients younger than 18 years.

Dialysis

Data not available

Other Comments

Administration advice:
-Prior to initiating treatment, bring all patients up to date with all immunizations per current guidelines.
-Administer as an IV infusion over 30 minutes.
-Do not administer as an IV push or bolus.
-After the infusion is complete, flush with 30 mL of sterile 0.9% Sodium Chloride.
-Every four week dosing is not recommended, as it did not demonstrate additional clinical benefit over every 8 week dosing.

Storage requirements:
-Refrigerate; protect from light.
-The infusion solution may be stored for up to four hours at 2C to 8C. Do not freeze.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility: Do not add other medicinal products to the prepared solution or intravenous infusion set.

Patient advice:
-Instruct patients to immediately report hypersensitivity symptoms during or following an infusion.
-Inform patients they may be more likely to develop infections and to report any signs of infection.
-Inform patients that progressive multifocal leukoencephalopathy (PML) has occurred with a different integrin receptor antagonist.
-Instruct patients to immediately report any new onset or worsening of neurological symptoms.
-Inform patients that elevated transaminase levels with or without elevated bilirubin have occurred.
-Instruct patients to report promptly any symptoms of liver injury such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice.

Hide